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Background
Meningococcal meningitis has been a terrifying public
health threat in countries of the Sahel and sub-Sahel
over the past 100 years. This geographical area has been
named the “African meningitis belt”. Older children and
young adults are particularly at risk during epidemics.
The mortality rate is usually 5% - 10%. A serogroup A
meningococcal conjugate vaccine was licensed in 2009.
Mass campaigns with MenAfriVac® covering 1-29 years
old have been conducted in several countries with assis-
tance from the GAVI Alliance. Long term health
impacts of MenAfriVac® can only be determined if
strong disease surveillance is in place. The study objec-
tive was to estimate the costs of meningitis surveillance
in Chad and determine resources needed for implement-
ing district case based surveillance.
Materials and methods
Data were collected for 2012. The ingredient approach
to costing was used. Data were collected from the
national laboratory and seven districts. In each district,
three primary care facilities and one district laboratory
was included. Resource utilization data were collected
from interviews. Resources were categorized according
to core surveillance functions (detect, report, analysis,
feedback, investigation, and response), and support func-
tions (training, supervision, communication, and co-
ordination). Unit costs were collected from financial
records of Ministry of Health and international partners.
An operational standard was developed for modeling
the incremental costs of upgrading the system.
Results
Optimal surveillance was severely hampered by limited
resources. One district laboratory had not been able to
conduct any analysis of cerebrospinal fluid (CSF) due to
lack of supplies. In 14 of the facilities staff was qualified
to perform lumbar puncture on patients with suspected
meningitis; patients were referred to district hospitals in
the remaining seven facilities. In three of the districts,
no meningitis cases were reported during 2012. In the
other four, reported cases varied between 43 and 232,
equivalent to between 11 and 89 per 100,000 popula-
tions. 11% of CSF was sent to the national laboratory
for confirmation.
Costs per detected case amounted to US$ 49, with
costs of lumbar puncture comprising 43% and labora-
tory analysis 41% of total costs. In facilities with no
detected cases, recourses spent on surveillance were
marginal.
Conclusions
Standard procedures for meningitis surveillance are miss-
ing due to lack of supplies at health facilities and labora-
tories and due to inadequate training of staff. While
investments are needed across the system, these are only
likely to be sustainable if activities are part of integrated
disease surveillance.
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